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Abstract 
Introduction: An institutional and centralized hospital-based tumour registry (TR) is the ideal supporting tool for the organization and 
management of clinical data in a comprehensive cancer centre. The purpose of this paper is to describe the development of the TR at 
the European Institute of Oncology (IEO), Milan, Italy, from its origin to its current applications. 
Material and methods: After a series of meetings with members of administrative, clinical, research and informatics departments, the 
TR was activated in March 2006 with the aim of collecting data on all the individuals referred to the institute, with or at risk of developing 
a tumour. It was implemented on an Oracle
TM-based interface. A minimum dataset of variables was defined and data collection was 
divided into four forms, which together gather all the relevant data on patients, tumours, treatments and subsequent events. 
Results: After a six-month pilot period, which involved the training of the tumour registrars, adjustments to the structure of the registry, 
development of a data quality control procedure and finalization of the operative protocol, since September 2006 the data collection has 
been fully operative. Five registrars have been chronologically entering data of all individuals who visited the IEO for the first time since 1 
January 2000. As of March 2009, data on 69,637 individuals and 43,567 tumours has been reviewed, recoded and registered in the TR. 
Twenty-two per cent of the tumours (n=9578) were first invasive primaries, diagnosed and treated in the IEO; the most common sites 
were breast (n=4972), lung (n=627), intestines (n=479) and prostate (n=376). 
Conclusion: The IEO TR has been proven functional and reliable in monitoring the activity of the hospital, allowing extraction of data 
from any subpopulation with characteristics of interest. The structured and centralized TR represents an important tool for our research-
oriented institution. 
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Introduction 
The European Institute of Oncology (IEO) aims at excellence in 
the prevention, diagnosis and treatment of cancer through high-
level clinical and scientific research. Since its opening in 1994, 
the number of individuals presenting for the first time to the IEO 
has increased year by year, reaching 38,500 in 2008. Thus, the 
need of a well-structured and centralized institutional database 
has become essential. Furthermore, to optimize the use of the 
great quantity of informa     tion, some obstacles typical of the 
organization and management of hospital data had to be 
overcome, such as the presence of many non-standardized 
databases, duplication of information and absence of 
centralized follow-up. For these reasons, the IEO tumour 
registry (TR) was planned, designed and finally activated in 
2006. 
The purposes of a hospital-based TR are to support the 
administration of the hospital, back up the clinical and scientific 
research and, above all, serve the needs of the patient [1]. In 
fact a TR can provide immediate reports on the activity of the 
hospital, document the cancer burden borne by the hospital for 
specific periods of time, provide background information useful 
for the design of clinical studies, extract data of any 
subpopulation with characteristics of interest and organize a 
centralized follow-up of patients, avoiding duplication of 
information and useless contact between the hospital and the 
patients. 
The aims of the present paper are to illustrate the development 
of the IEO TR, from its origin to its current applications, and to 
describe the case-mix of our institute. We will report data from 
its first three years of activity, including data on all individuals 
presenting to the institute between 2000 and 2002, already 
having or being at risk of developing a tumour. 
  
Material and methods 
Brief history 
The TR project was developed in many successive phases, 
starting with a series of meetings and discussions on 'who' an 
'what' to include. A group of experts, consisting of physicians, 
information technology (IT) specialists, data managers, 
administrative personnel and biostatisticians had regularly met 
for almost two years to discuss the format and the data to be 
collected. An important part of the planning was also dedicated 
to visiting and contacting other hospital-based cancer registries, 
in order to learn from already established realities. Thereafter, 
the database was designed and tested. It was decided to 
implement the TR using an Oracle
TM-based interface. The 
implementation, completed in February 2006, was managed in 
the Division of Epidemiology and Biostatistics, with the help of 
the IT division. The next phase involved the selection and 
training of dedicated data registrars. The project finally got off 
the ground in March 2006, and at present five dedicated 
persons are working full time on entering the data. Data quality 
control and data management are carried out by two data 
managers and two biostatisticians. 
Eligibility criteria 
We agreed to collect information on all individuals presenting at 
the IEO since its opening, either with a tumour or at risk of 
developing one. We also decided to collect information on 
patients with previous invasive tumours, either treated at this 
institute or elsewhere. In order to gain entry in the TR, patients 
must have: (1) the IEO unique identification number, assigned 
to the individual at the first visit; and (2) at least one medical 
report (i.e., pathological report or diagnostic examination) 
accessible from the institute's intranet. 
Information collected 
A minimum dataset of variables was defined, to establish the 
best compromise between synthesis and informativeness. Data 
collection is divided into four forms: on the first form personal 
data (i.e. sex, date of birth) and information on survival (i.e. date 
of last contact, date of last visit, vital status, cause of death) are 
recorded. The type of record is registered in this form. The 
following types of record are assigned to each individual. 
1.  Visit: a healthy individual comes to the IEO for either a 
visit or a genetic counselling. 
2.  Anamnesis: the patient, at the moment free of 
disease, reports on a tumour diagnosed in the past 
and already treated and cured elsewhere. 
3.  Diagnosis: diagnosis of tumour is made at the IEO 
and the patient decides to be treated and followed up 
elsewhere. 
4.  Second opinion: the patient or the patient's parents 
come to the IEO and ask for an opinion on a diagnosis 
and/or a treatment proposed elsewhere. 
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Figure 1: The structure of the IEO tumour registry
5.  Long: the patient receives at least one treatment at the 
IEO. 
Detailed information on the patient's tumour(s) (i.e. date of 
diagnosis, morphology, topography, TNM staging, ordinal 
number of the tumour for multiple tumours) is recorded on the 
second form, together with some epidemiological information 
(i.e. familiarity, height and weight at diagnosis and smoking 
habits). The third form is dedicated to the treatment strategy, 
where every therapy is classified as administered or proposed. 
The fourth catalogues, chronologically, all following events, 
tracing the whole history of the disease. 
It is important to note that the amount of data collected will vary 
according to the type of record: the completion of all four forms 
only occurs for patients coded as 'Long'. For patients coded as 
'Anamnesis', 'Diagnosis' or 'Second opinion' only the personal 
data form together with date of diagnosis, place of diagnosis, 
the IEO histopathological identification code (if any), topography 
and morphology are registered. For patients coded as 'Visit' 
only the personal data form is completed. 
Invasive and in situ tumours are always collected, whereas 
benign tumours or negative histologies are collected only if the 
patient undergoes a major surgical procedure in the IEO. 
Examples of benign tumours/negative histologies we collect are: 
adenoma of the thyroid after thyroidectomy, fibroadenoma after 
quadrantectomy and negative histology after hysterectomy. 
The structure of the TR is represented in Figure 1. The patient 
is the basis of the structure. Zero, one or more tumours can be 
linked to the patient. Zero, one or more treatments and events 
can be linked to each tumour. 
Systematized Nomenclature of Medicine-Clinical Terms 
(SNOMED CT) [2] is used to classify tumours according to 
topography and morphology except for haematopoietic tumours, 
for which we use the World Health Organization (WHO) ICD-10 
classification [3]. Clinical and pathological staging is based on 
the TNM system [4], whether the fifth or the sixth edition 
according to the date of diagnosis. Cause of death is based on 
the WHO ICD-10 classification [3]. 
Sources of data, data entry and quality control 
The IEO TR data entry is completely paperless, as all the 
information derives from computerized sources: the IEO 
patients' administrative database (personal information is 
automatically visible on the personal data form), medical reports 
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accessible on the IEO intranet, online databases (surgery, 
laboratory medicine, pathology, etc.) and patients' clinical 
dossier, which are all digitalized and accessible online. 
Five data registrars work full time on data entry. Each one has 
specialized in a particular tumour or set of tumours in order to 
achieve specific knowledge and abilities. Data quality control 
and data management are carried out by two data managers 
and two biostatisticians. A data manager randomly reviews data 
entered by a registrar, and the two discuss potential mistakes. A 
field was created in which notes regarding which cases are 
revised by a data manager and which are not inserted. 
Furthermore, in order to clarify any doubt on specific cases, a 
medical doctor was chosen from each division as a referent to 
address questions to. 
 
Results 
A six-month pilot period (March to August 2006) was necessary 
to train the registrars, adjust the structure of the registry, 
develop a data quality control procedure and edit the operative 
protocol. Since September 2006, the data entry has been 
running at top speed. We started by entering individuals who 
presented for the first time to the IEO in the year 2000 in a 
sequential fashion. By March 2009, 69,637 individuals had been 
entered in the TR, corresponding to individuals who came for 
the first time to the IEO between 2000 and 2002, not 
necessarily presenting with a tumour. In Table 1, some 
characteristics of these individuals are reported. Approximately, 
one out of four was classified as 'Long', as he/she received at 
least one treatment in the IEO. Only 1.6% of individuals were 19 
years old or less, as our institute does not treat paediatric 
tumours. 
Overall, 39,480 individuals out of 69,637 had one or more 
tumours. Information on a total of 43,567 tumours was 
collected, with an average of 1.1 tumours per person. 
Frequencies by site, malignancy, place of diagnosis and place 
of surgery are reported in Table 2. 
In Table 3, we reported only the first invasive primary tumours, 
diagnosed and treated in the IEO (n=9578), which represent the 
typical subgroup of tumours used for epidemiological 
retrospective studies. Breast was the most frequent tumour site 
by far (n=4972), followed by lung (n=627), intestines (n=479) 
and prostate (n=376). In order to show an example of the 
reports that can be easily obtained from the TR, we included 
some additional information for the most frequent tumour sites: 
breast (women only), colorectal, lung, non-Hodgkin lymphoma, 
ovary, prostate, sarcoma, skin melanoma and tongue 
(
A recent paper entitled 'Analysis of local and regional 
recurrences in breast cancer after conservative surgery' 
represents the first study conducted on the data of the TR [5]. It 
consisted of a multistage analysis of local, regional and distant
Although it was decided that researchers or clinicians would not 
have direct access to the TR, we have established a system to 
collect and answer requests. Data extrapolation and analysis 
are managed in the Division of Epidemiology and Biostatistics. 
Regarding information on events and survival, although patients 
in the TR had a theoretically adequate follow-up, with a median 
of six years, we preferred not to report any result, as we have 
not performed a detailed analysis of the quality of the follow-up 
yet. By now, vital status (dead/alive) and events are based on 
passive follow-up, with an accuracy depending on the site or 
other characteristics of the tumours. For example, since our 
institute produces many publications in breast cancer field, 
follow-up information on patients suffering from that tumour is 
updated more frequently compared to patients with other 
tumours. Survival analyses on different tumours might have 
been incomparable. By 2010, after a detailed analysis of the 
follow-up information collected in our institute, an active 
centralized follow-up will be organized and started. 
This paper presents the first three years of activity of the IEO 
TR, specifically data on all individuals presenting for the first 
time to the institute in the years 2000–2, already having or being 
at risk of developing a tumour. This first analysis of the TR data 
demonstrated that the registry can support the administration in 
monitoring the hospital activity, be a supporting tool for the 
clinical practice as well as for epidemiological/basic research, 
play a key role in the production of publications on any 
subpopulation with characteristics of interest and, above all, 
improve patient management and knowledge of the 
disease. 
Discussion 
 
Finally, we calculated that, on average, it took about ten 
minutes to enter a case, that is six cases per hour. The time 
varied depending especially on the type of record: 22 minutes 
for a long case, two minutes for a visit and nine minutes for 
other types of record. By the end of 2009, data of all individuals 
who referred to the IEO for the first time in the years 2000–4 will 
be collected, for a total of about 125,000 individuals and 80,000 
tumours. 
Appendices A–I]. 
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Table 1: Characteristics of individuals
a 
recurrences, performed on data of 2784 women treated for early 
breast cancer by quadrantectomy and whole breast irradiation 
at the IEO. The authors concluded that 'local and regional 
recurrences after breast-conserving surgery are rare events. 
They are markers of tumour aggressiveness and indicators of 
an increased likelihood of distant metastases'. 
As shown in this paper, we can easily monitor the activity of the 
IEO and extrapolate data from any subpopulation with 
characteristics of interest. We strongly believe that a well-
structured and centralized TR is a necessary tool for our, and in 
fact any, institution where research is a fundamental part of its 
activity. 
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Table 2: Tumours by site
a 
Table 3: First invasive primaries diagnosed and treated in the IEO
a by site, gender and age 
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Appendices 
Appendix A: Characteristics broken down by tumour 
type: breast cancer (women only) 
 
Table A1: Characteristics at diagnosis 
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Table A2: Treatment strategy 
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Figure A1: Place of surgery 
   
Fig A2: Familiarity for breast and non-breast cancer
b 
 
 
  
a‘Long' record type (at least one treatment in IEO); pathological diagnosis in IEO (at least a slide review in IEO); 
bInformation is missing for some patients; 
cNo evidence of primary tumour after neoadjuvant treatment. RT: Radiotherapy; HT: hormonotherapy; CT: chemotherapy and/or monoclonal antibody. 
NOS: not otherwise specified. 
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Appendix B: Characteristics broken down by tumour 
type: colorectal cancer (468 first invasive primaries 
treated and diagnosed in IEO
a) 
 
 
Table B1: Characteristics at diagnosis 
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Table B2: Treatment strategy 
 
 
Figure B1: Place of surgery  Figure B2: Specific tumour site 
 
a'Long' record type (at least one treatment in IEO); pathological diagnosis in IEO (at least a slide review in IEO); 
bInformation is missing for some patients; 
cNo evidence of primary tumour after neoadjuvant treatment. RT: radiotherapy; HT: hormonotherapy; CT: chemotherapy and/or monoclonal antibody; 
NOS: not otherwise specified
 14  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2009, 3:149 
 
Appendix C: Characteristics broken down by tumour 
type: lung cancer (627 first invasive primaries treated 
and diagnosed in IEO
a) 
 
 
Table C1: Characteristics at diagnosis 
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Table C2: Treatment strategy   
 
 
Figure C1: Place of surgery  Figure C2: Smoking status at diagnosis
b 
 
 
a'Long' record type (at least one treatment in IEO); pathological diagnosis in IEO (at least a slide review in IEO); 
binformation is missing for some patients; 
cNo evidence of primary tumour after neoadjuvant treatment. RT: radiotherapy; HT: hormonotherapy; CT: chemotherapy and/or monoclonal antibody.
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Appendix D: Characteristics broken down by tumour 
type: non-Hodgkin lymphoma (225 first invasive 
primaries treated and diagnosed in IEO
a) 
Table D1: Characteristics at diagnosis 
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Table D2: Treatment strategy 
 
 
 
Figure D1: Place of surgery 
 
a'Long' record type (at least one treatment in IEO); pathological diagnosis in IEO (at least a slide review in IEO); 
bWHO classification applied; 
cInformation 
is missing for some patients. pS: pathological stage. RT: Radiotherapy; HT: hormonotherapy; CT: chemotherapy and/or monoclonal antibody. NHL: non-
Hodgkin lymphoma; L: lymphoma. 
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Appendix E: Characteristics broken down by tumour 
type: ovarian cancer (241 first invasive primaries 
diagnosed and treated in IEO
a) 
 
 
Table E1: Characteristics at diagnosis 
 
 19  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2009, 3:149 
 
 
Table E2: Treatment strategy 
 
 
Figure E1: Place of surgery  Figure E2: Familiarity for ovarian and non‐ovarian cancer 
 
 
a'Long' record type (at least one treatment in IEO); pathological diagnosis in IEO (at least a slide review in IEO); 
bInformation is missing for some patients. 
HT: Hormonotherapy; CT: chemotherapy and/or monoclonal antibody; MRT: metabolic radiotherapy; NOS: not otherwise specified. 
 20  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2009, 3:149 
 
 
Appendix F: Characteristics broken down by tumour 
type: prostate (376 first invasive primaries treated 
and diagnosed in IEO
a) 
 
 
Table F1: Characteristics at diagnosis 
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Table F2: Treatment strategy 
 
 
Figure F1: Place of surgery  Figure F2: Familiarity for prostatic and non‐prostatic cancer 
 
 
 a'Long' record type (at least one treatment in IEO); pathological diagnosis in IEO (at least a slide review in IEO); 
binformation is missing for some patients; 
RT: radiotherapy; HT: hormonotherapy; CT: chemotherapy and/or monoclonal antibody. NOS: not otherwise specified. 
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Appendix G: Characteristics broken down by tumour 
type: sarcoma (161 first invasive primaries treated 
and diagnosed in IEO
a) 
 
 
Table G1: Characteristics at diagnosis 
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Table G2: Treatment strategy 
 
 
Figure G1: Place of surgery 
a'Long' record type (at least one treatment in IEO); pathological diagnosis in IEO (at least a slide review in IEO); 
binformation is missing for some patients. 
RT: Radiotherapy; HT: hormonotherapy; CT: chemotherapy and/or monoclonal antibody; NOS: not otherwise specified. 
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Appendix H: Characteristics broken down by tumour 
type: skin melanoma (370 first invasive primaries 
diagnosed and treated in IEO
a) 
 
 
Table H1: Characteristics at diagnosis 
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Table H2: Treatment strategy 
 
Figure H1: Place of surgery  Figure H2: Breslow thickness 
b 
 
a'Long' record type (at least one treatment in IEO); pathological diagnosis in IEO (at least a slide review in IEO); 
binformation is missing for some patients. 
RT: Radiotherapy; HT: hormonotherapy; CT: chemotherapy and/or monoclonal antibody. NOS: not otherwise specified. 
 
 
 
 
 26  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2009, 3:149 
 
Appendix I: Characteristics broken down by tumour 
type: tongue (90 first invasive primaries diagnosed 
and treated in IEO
a) 
 
 
Table I1: Characteristics at diagnosis 
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Table I2: Treatment strategy 
 
 
Figure I1: Place of surgery  Figure I2: Type of surgery 
 
a'Long' record type (at least one treatment in IEO); pathological diagnosis in IEO (at least a slide review in IEO); 
binformation is missing for some patients; 
RT: radiotherapy; HT: hormonotherapy; CT: chemotherapy and/or monoclonal antibody.
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